Market Overview

Vetr Crowd Upgrades Bluebird After Trump Presser

Related BLUE
Barclays: Editas Medicine On Track To File New Drug App Next Year
9 Notable Biotechs Presenting At This Year's ASH Meeting
Your Daily Pharma Scoop: Gilead CAR-T Potential, Egalet Surges, Aerie Launches Mid-Stage Study (Seeking Alpha)

On Wednesday, the Vetr crowd upgraded their rating for bluebird bio Inc (NASDAQ: BLUE), from 2.5 Stars (Sell) issued two days ago, to 3.5 Stars (Buy). Crowd sentiment for the stock is generally cautious, with 66 percent of Vetr user ratings bearish.

The gene therapy company experienced the same drop many biotech firms experienced in the wake of President-elect Donald Trump's first press conference following his election win in November. The sector saw an immediate selloff following the President-elect's comment about the cost of consumer drug prices.

Shares of bluebird bio fell over 5 percent to $64.70 immediately following the remark made around noon on January 11. The stock bounced back slightly as traders capitalized on the market's reaction. The stock still finished the day down at $65.05.

See how crowdsourced ratings could help you time the market.

Currently, the Vetr crowd's average target price for the stock is up at $69.48, which is well below the average analyst target price of $88.77. Less than 2 percent of Vetr users are holding BLUE in their watch lists.

Latest Ratings for BLUE

Nov 2017Evercore ISI GroupDowngradesOutperformIn-Line
Nov 2017SunTrust Robinson HumphreyMaintainsBuyBuy
Nov 2017Morgan StanleyUpgradesUnderweightEqual-Weight

View More Analyst Ratings for BLUE
View the Latest Analyst Ratings

Posted-In: VetrBiotech Upgrades Crowdsourcing Analyst Ratings


Related Articles (BLUE)

View Comments and Join the Discussion!

Partner Center